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Abstract 
In adults, cerebral metastases are the 
most common intracranial tumors, and 
their incidence has been rising in the last 
decades. The median interval between the 
diagnosis of the primary cancer and the 
detection of brain metastasis is relatively 
short, generally around one or two years.  
This study made a selection of six cases 
with a more than five years delay until the 
diagnosis of a cerebral metastases, from 
over 246 patients with brain metastases, 
admitted in our department, between 2006-
2010. All six patients underwent surgery for 
their primary neoplasm, prior to 
neurosurgical diagnosis and treatment.  
We found 6 patients, having renal, breast 
or lung cancer, in which the delay between 
diagnosis of the primary tumor and that of 
the brain metastases started from 5 years 
and reached even 18 years. 
In all cases, this delay was longer than 
the median interval found in the most 
neurosurgical series. Very probably the 
immune system plays a major role in 
controlling recurrences and new metastases 
in the nervous system 
Keywords: cancer, cerebral metastases, 
long delay cerebral metastases, prognostic 
factors 
Introduction 
Brain metastases represent a significant 
source of morbidity and mortality in 
patients with systemic cancer. Nowadays, 
cancer patients have a longer life expectancy 
because of the important advances in cancer 
diagnosis and therapy. 
The incidence of brain metastases is 
difficult to determine with precision. In 
earlier neurosurgical series the overall 
incidence of cerebral metastases was 20%- 
30% for all patients with systemic cancer 
(20). Estimates based on more recent series 
and autopsy studies show a much higher 
incidence of brain metastases, with 
incidences varying between 8.3 to 11.1 per 
100.000 individuals (12). Approximately 
40% of intracranial neoplasms are 
metastatic (10, 23). These estimates place 
brain metastases first in frequency among 
all intracranial tumors, before intracranial 
glioma and meningioma (18, 21, 27). 
The histological type of the primary 
tumor appears to be the major factor of the 
frequency and pattern of intracranial 
spread. Multiple, large autopsies series 
suggest that, in order of decreasing 
frequency, lung, breast, melanoma, renal 
and colon cancer are the most common 
primary tumors that metastasize to brain 
(10, 12, 21, 27). Primary lung tumors 
account for 30% to 60% of all brain 
metastasis cases (13, 15). Breast cancer 
ranks second, contributing 10% to 30% (13, 
15) of all brain metastases among women 
(21), and renal cancer has a frequency of 
11% (2, 23). When the ability of a primary 
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tumor to spread to the brain is considered, 
melanoma ranks first followed by lung and 
breast cancers (1, 16, 19). 
The median interval between the 
diagnosis of the primary cancer and the 
detection of brain metastasis is relatively 
short, generally around one or two years (4, 
24). This study made a selection of six cases 
with a more than five years delay. 
Material and methods 
We made a retrospective study over 246 
patients with brain metastases, which were 
admitted and operated in our department, 
the Neurosurgery Clinic of the Institute of 
Cerebrovascular Diseases “Prof. Dr. V. 
Voiculescu” – Bucharest, between 2006-
2010. In this series, we found 6 patients, 
having renal, breast or lung cancer, in 
which the delay between diagnosis of the 
primary tumor and that of the brain 
metastases was longer than the median 
interval found in the most neurosurgical 
series. The time interval was measured 
between the month recorded from the 
primary cancer surgery and that for the 
cerebral tumor surgery. All patients 
underwent surgery for their primary 
neoplasm, prior to the diagnosis of the 
intracranial tumor. We performed a radical 
surgical treatment with removal of the 
entire cerebral metastases, proved by 
postoperative contrast CT scans. 
Ilustrative case 
Patient C.L., female, 69 years old, was 
admitted in our clinic in October 2010. She 
complained of persistent headache and 
balance disorders. Neurological 
examination revealed a right pyramidal 
syndrome and motor aphasia. Contrast 
cerebral CT scan showed a large, relatively 
well-circumscribed tumor, located in the 
left frontal lobe, with nonhomogenous 
contrast enhancement and important 
peritumoral edema. 
From her previous pathological history 
we noted that in 1992 she underwent 
surgery for a left breast carcinoma when a 
left mastectomy was achieved. The 
histological exam showed an infiltrating 
ductal carcinoma. Postoperatory, the patient 
underwent radiation therapy and followed a 
chemotherapy protocole. In 1998, she was 
operated for a right breast mastosis, when a 
Pattey-type mastectomy was performed. 
The patient underwent surgery for her 
left frontal lobe tumor. We performed a 
frontal craniectomy, located on the lesion, 
and achieved a total gross removal of a 6 
cm. in diameter tumor, with central 
necrosis. The histological exam revealed a 
metastasis from a breast ductal carcinoma. 
The patient followed postoperative 
radiation therapy with a total radiation dose 
of 60Gy. 
The last clinical examination, performed 
12 months after surgery, proved a good 
general and neurological health condition 
of the patient. Control cerebral CT scan 
showed absence of any tumor recurrences. 
The interval of time between the 
diagnosis of the breast cancer and that of 
cerebral metastasis was18 years. 
Results 
As we mentioned, our selection criteria 
was a long delay between the diagnosis of 
the cancer and the detection of the cerebral 
metastases. Two patients with renal cancer 
had the same 7 years delay between the 
diagnosis of the cancer and that of cerebral 
metastasis. Two patients, operated for a 
breast cancer, had a delay of 8, respectively 
18 years. 
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Figure 1 A Preoperative contrast cerebral CT scan 
showing a large left frontal tumor, with important 
peritumoral edema and shifting of the midline;  
B Postoperative contrast CT scan (12 months after 
surgery) showing a total gross resection of the frontal 
metastases and lack of local recurrence. 
 
One patient with a laryngian neoplasm, 
than operated on for a lung metastasis, 
showed two cerebral tumors with a delay of 
7 years from the diagnosis of his cancer. 
The last patient, operated for a lung cancer, 
presented a cerebral metastasis after 5 years 
from the diagnosis of his lung neoplasm. 
 
Statistic dates Case1 Case 2 Case 3 Case 4 Case 5 Case 6
Sex F M F F M M 
Age 57 57 50 69 54 50 
Primary cancer 
(date of surgery) 
Renal 
cancer 
(02. 
2002) 
Renal cancer 
(10.2002) 
Breast 
cancer 
(12.2000) 
Breast 
cancer 
(03.1992) 
Laryngian 
cancer 
(06.2002) 
Lung 
cancer 
(04.200
5) 
Cerebral metastasis 
surgery 
11.2009 10.2009 10.2008 10.2010 05.2009 07.2010 
No. of cerebral 
metastases 
1 1 1 1 2 1 
Length of time 
interval (years) 
7 7 8 18 7 5 
Postoperative 
follow-up  (months) 
19 14 26 12 10 10 
Systemic metastases No Yes (bone 
metastasis; 
02.2007) 
No No Yes (lung 
metastases; 
09.2007) 
No 
Postoperative  
cerebral 
radiotherapy/ 
systemic 
chemotherapy 
Yes/yes Yes/no No/no Yes/no Yes/yes Yes/no 
 
Discussion 
The histology of the primary tumor 
appears to be the major dictator of the 
frequency and pattern of intracranial 
extension. Virtually any type of cancer has 
the ability to produce brain metastases. Half 
of the patients with brain metastases in 
autopsy series had lung or breast cancer as 
the primary tumor (14, 22). 
The process of tumor metastasis is 
highly selective and consists of a series of 
sequential, interrelated steps. To produce 
clinically relevant lesions, metastatic cells 
must complete all steps of this process. 
More than a century ago, Stephen Paget 
questioned whether the organ distribution 
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of metastases produced by different human 
neoplasms was due to chance. He analyzed 
more than 1.000 autopsy records of women 
with breast cancer. His research 
documented a nonrandom pattern of 
metastasis, suggesting that the process was 
not due to chance but rather, that certain 
tumor cells (the "seed") had a specific 
affinity for the milieu of certain organs (the 
"soil"); metastases resulted only when the 
seed and soil were compatible (17). Some 
40 years later, J. Ewing challenged Paget's 
"seed and soil" theory and hypothesized that 
metastatic dissemination occurs by purely 
mechanical factors that are a result of the 
anatomical structure of the vascular system 
(7). These explanations have been evoked 
separately or together to explain the 
metastatic site preference of certain types of 
neoplasms. It is proved today, that only 
certain cancer cell lines (cell clones) could 
cover all the stages of the metastatic cascade 
process (8). Also, the development of a 
metastasis in certain area of the central 
nervous system is specific to selected clone 
cells depending on the histology of the 
primary tumor (8, 9). 
In our study were reviewed brain 
metsteses from lung, breast and renal 
cancers. Therefore, we selected few 
informations about these neoplasms. 
Primary lung tumors account for 30% to 
60% of all cases of brain metastasis (14, 16). 
Lung cancer ranks second among all 
cancers in its tendency to invade the brain 
(5,14).  
Of patients with lung cancer, 18% to 
65% will develop brain metastases and the 
specific histology of the primary lung 
tumor is very important in determining 
metastatic frequency (5, 22). There are five 
histological subtypes of lung cancer: small 
cell lung cancer, squamous cell carcinoma, 
adenocarcinoma, large cell cancer and 
carcinoid tumor.  
Indeed, more than 40% of patients with 
small cell lung cancer and lung 
adenocarcinoma have brain metastases in 
clinical series or at autopsy (5). It represents 
more than twice the rate of metastasis 
found with the other types of lung cancer 
such as squamous cell carcinoma (5,22).  
In a clinical series of patients with brain 
metastases from lung cancer in Turkey 
(22), adenocarcinoma, epidermoid 
carcinoma, and small cell carcinoma gave 
rise to 84% of these metastatic lesions. In a 
clinical series of patients presenting with 
brain metastases as the first sign of their 
malignancy at the Gustave-Roussy Institute, 
France, 44% had adenocarcinoma and 30% 
had undifferentiated or small cell lung 
carcinoma, compared with only 12% who 
had squamous cell lung carcinoma (12).  
The median interval between the 
diagnosis of lung cancer and the detection 
of brain metastasis falls between two and 
nine months and is shorter than is seen for 
other cancers (16, 22). In our study, the 
delay was a few times longer, 5 years for the 
lung tumor and respectively 7 years for the 
laryngian one. For the lung neoplasm the 
histological result was adenocarcinoma. 
Primary breast cancer ranks second to 
lung cancer as the most frequently 
occurring primary tumor in patients with 
brain metastases. Among women, breast 
cancer is the most common cause of brain 
metastasis, resulting in 5% to 30% of all 
brain metastases (25, 26). Breast cancer 
ranks third, after lung cancer and 
melanoma, among primary cancers in its 
tendency to metastasize to the brain, and 
approximately 20% to 30% of patients with 
breast cancer will develop a brain metastasis 
(21, 26). 
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Brain metastases from breast cancer 
typically occur late in the course of the 
disease, between 2 and 3.3 years after 
diagnosis (16,22). In our study, both 
patients had a breast ductal adenocarcinoma 
metastasis, and had an 8 respectively 18 
years delay.   
Primary renal cancer frequently 
metastasizes to the brain. In an autopsy 
series, the frequency of brain metastases in 
renal adenocarcinoma patients was 11% (2, 
23).  In a clinical series by Harada et al. 
5.5% of 325 patients who had renal cell 
carcinoma that was treated at Osaka 
University Hospital from 1957 to 1993, 
developed brain metastases (11).  
The median interval between diagnosis 
of renal cancer and brain metastasis caused 
by it ranges from 1 year to 2.3 years (3, 11). 
In our study both patients showed a same 7 
years time interval and had clear cell 
carcinoma metastases on histological exams. 
Long delay between diagnosis of the 
primary tumor and the development of the 
brain metastasis represents, in most series, a 
favorable prognostic factor associated with a 
longer median survival (6, 19, 24). Other 
favorable prognostic factors are: primary 
cancer under control, absence of 
extracranial metastases, Karnofsky score > 
70, age under 60, female gender and, of 
course, gross total resection of the 
metastasis. 
The median patient survival time after 
surgical excision of a single brain metastasis 
is 9 to 14 months, depending on such 
factors as the type of primary cancer, length 
of time between diagnosis of the primary 
tumor and diagnosis of brain metastasis, 
neurological performance status, and 
presence or absence of systemic disease (6, 
19). 
Contrary to classical teaching, recent 
reports demonstrated that surgery improves 
the survival of patients with multiple brain 
metastases, so long as all the lesions can be 
removed. These good results are achieved 
only in patients with two or three 
metastases and it must be emphasized that 
for resection to be beneficial, all the lesions 
must be resected (4).  
Conclusions 
Generally, the longest survival intervals 
were recorded in patients operated on for 
breast, renal and lung cerebral metastases, 
and the shortest intervals in patients with 
melanoma metastasis. All our six patients 
demonstrated at their last control registered 
in our clinic records, a good general and 
neurological performance status. None of 
them presented cerebral recurrences at the 
control CT scan examination. In all cases 
we performed a radical surgical treatment 
with removal of the entire tumoral mass. 
Because  a long interval between the 
diagnosis of the primary cancer and that of 
cerebral metastases plays an important role 
in obtaining a longer patient survival an 
aggressive surgical approach should be 
encouraged in these selected cases. 
In the articles that we had reviewed we 
did not find a clear explanation of this long 
delay in metastatic process. Very probably 
the immune system plays a major role in 
controlling recurrences and new metastases 
also in the nervous system. Conceivably in 
such cases (as, probably, in ours), some 
neoplastic nidi were kept dormant by an 
uncertain balance between the neoplastic 
aggressiveness and the defensive factors of 
the organism. As long as this balance 
operated, the metastases were prevented 
from developing enough to give rise to 
clinical symptoms and hence detection. 
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